Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_634d7355c2673489b2f4f800541770bb |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0318 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2440-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2814 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2228 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0276 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
filingDate |
2008-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_382753db6d53ba4d971ac067ff9db85f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0470576243a517686eb4671cf3a6818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_724e1c382328d859c8b6cca44a914a34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b557f2be0a85320b36d0ba107378a4c |
publicationDate |
2010-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2010278743-A1 |
titleOfInvention |
Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling |
abstract |
Methods for treating or preventing tauopathies and/or Aβ amyloidosis by modulating CRF receptor signaling. Accumulation of hyperphosphorlyated tau protein in the CNS may be reduced by administration of CRF-R1 selective antagonists and/or CRF-R2 selective agonists. For example, in some aspects, methods for preventing the onset of Alzheimer's disease by administration of CRF-R1 selective antagonist are provided. |
priorityDate |
2007-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |